<DOC>
	<DOCNO>NCT01495481</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety dexmedetomidine acute termination Supraventricular Tachycardia ( SVT ) .</brief_summary>
	<brief_title>Dexmedetomidine Adenosine : Therapeutic Use SVT</brief_title>
	<detailed_description>In 2006 investigator find dexmedetomidine , alpha-2 adrenergic agonist primarily sedative property , possess additional anti-arrhythmic property . So far investigator find dexmedetomidine ability prevent terminate arrhythmia like atrial ectopic tachycardia ( 85 % success ) junctional ectopic tachycardia ( 75 % success ) . The dramatic effect however observe acute termination reentrant SVT success rate &gt; 96 % . More importantly find dexmedetomidine terminates SVT without cause sinus pause asystole ( frequently see adenosine ) thus avoid feel `` impending doom '' . In study adenosine compare head head dexmedetomidine cross study , safety efficacy give termination SVT electrophysiology ( EP ) lab . Additional EP parameter measure elucidate exact site dexmedetomidine 's mechanism action .</detailed_description>
	<mesh_term>Tachycardia</mesh_term>
	<mesh_term>Tachycardia , Supraventricular</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients age 5 30 year old , schedule cardiac electrophysiology study evaluation reentrant SVT Severe Heart Failure Presence antiarrhythmic medication within 24 hour enrollment Third degree heart block Sick Sinus Syndrome</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Supraventricular Tachycardia</keyword>
	<keyword>SVT</keyword>
	<keyword>Reentrant Tachycardia</keyword>
	<keyword>Dexmedetomidine</keyword>
	<keyword>Adenosine</keyword>
</DOC>